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ABSTRACT
Introduction. Chromosomal aberrations are rare but important causes of various movement disorders. In cases of movement 
disorders associated with dysmorphic features, multiorgan involvement and/or intellectual disability, the identification of cau-
sative chromosomal aberrations should be considered.
Aim of the study. The purpose of this article was to summarise clinical findings in six patients with dystonia and two with 
parkinsonism and identified chromosomal aberrations in a single-centre prospective study.
Materials and methods. 15 adult patients with dystonia or parkinsonism were referred to array comparative genomic hybri-
disation (aCGH) testing from our Department of Neurology between 2014 and 2019. Additionally, one patient had a karyotype 
examination. Detailed clinical, psychological and radiological diagnostics were performed in each case.
Results. Chromosomal aberrations were identified in six patients with dystonia and two with parkinsonism. Two patients were 
identified with aberrations associated with de Grouchy syndrome. We also reported generalised dystonia in patients with 
deletion in 3q26.31 and duplication in 3p26.3, as well as dystonia and hypoacusis in a patient with duplication in Xq26.3. One 
patient was diagnosed with duplication in 21q21.1. Early-onset parkinsonism was a manifestation of deletion in the 2q24.1 re-
gion. Late onset parkinsonism was also present in the patient with the most severe aberrations (duplication 1q21.1q44; deletion 
10p15.3p15.1; deletion 10q11.21).
Conclusions. Dystonia and parkinsonism are possible manifestations of chromosomal aberrations. Chromosomal aberrations 
should be excluded in patients with early-onset movement disorders and concomitant dysmorphic features and/or intellectual 
disability. It is important to include this cause of movement disorders in future classifications. aCGH can be a valuable diagnostic 
tool in the evaluation of movement disorder aetiology.
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Introduction
Dystonia and parkinsonism are among the most commonly 
diagnosed movement disorders. There is, however, no specific 
mention of chromosomal aberrations as a cause of dystonia in the 
IPDMS dystonia classifications [1, 2]. In parkinsonism, a genetic 
background is usually observed in those patients with disease 
onset before the age of 50 or with a positive family history [3, 4].
Structural aberrations are caused by a rearrangement of 
the genetic material. They can be associated with a very broad 
clinical spectrum, from asymptomatic or benign to lethal. 
The study by Dale et al. suggested that up to 28% of children 
with movement disorders of suspected genetic aetiology have 
chromosomal abnormalities [5]. 
Chromosomal aberrations in selected movement disorder 
patients are important to identify. They cause multiorgan 
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involvement, and extended diagnostic measures need to be 
undertaken in order to exclude cardiac and endocrine system 
abnormalities. Assessment of chromosomal imbalances may be 
performed using standard karyotyping or molecular diagnos-
tics with array comparative genomic hybridisation (aCGH). 
aCGH is based on identifying differences in fluorescence 
signal intensity between the patient and reference DNA sam-
ples hybridised to the array. Its main limitation is an inability 
to detect balanced aberrations. It has a higher resolution of 
~100 kbp vs. 5 Mbp for karyotype examination. 
An American expert consensus statement from 2010 iden-
tified aCGH as a first-line diagnostic tool for the postnatal 
testing of patients with autism-spectrum disorder, intellectual 
disability, and multiple congenital anomalies [6]. aCGH is of-
ten performed in children with developmental delays, epilepsy 
or multiorgan manifestations, but rarely in adult patients with 
movement disorders. Some reports have suggested that it may 
be of value, particularly when atypical features appear in pa-
tients with otherwise acknowledged syndromes. This includes 
the paper by Lohmann et al. on the identification of causes of 
dopa-responsive dystonia and eye and skeletal abnormalities in 
a large family, in which aCGH examination revealed deletion 
on chromosome 6, including the CGH1 gene [7]. Similarly, 
a case of brain-lung-thyroid syndrome was described in a girl 
with additional immunodeficiency. Negative PCR and Sanger 
sequencing led to an aCGH examination, where the deletion 
of 3.32 Mbp in the chromosome 14q13.2-q21.1 region was 
detected, including genes NKX2-1 but also genes involved in 
immunological response [8].
A few other studies have reported chromosomal aberration 
as a potential cause of early-onset PD. An aCGH study in pa-
tients with early-onset levodopa-responsive parkinsonism and 
intellectual disability revealed partial trisomy in 4q [9]. The 
best-characterised chromosomal aberration associated with 
PD is 22q11 deletion. The study by Mok et al. revealed eight 
carriers from a total cohort of 9,387 PD patients confirmed 
by aCGH examination [10]. In a recent publication, an aCGH 
examination revealed cases with duplication of the SNCA gene 
and heterozygous intragenic deletion of the GBA gene in 99 PD 
subjects with a positive family history [11].
In our paper, we describe a cohort of adult patients with 
neurodevelopmental disorders and concomitant dystonia or 
parkinsonism and chromosomal aberrations. 
Materials and methods
We prospectively identified and examined patients hos-
pitalised in the Department of Neurology between 2006 and 
2019 in whom dystonia or parkinsonism caused by karyotype 
abnormalities were suspected. Early onset of neurological 
symptoms, the progressive nature of symptoms, neurodevel-
opmental delay or negative metabolic investigations led to 
aCGH or karyotype examinations. Fifteen adult patients with 
dystonia or parkinsonism were referred to cytogenetic testing 
from our Department of Neurology between 2014 and 2019. 
In 7/15 patients, aCHG testing indicated pathogenic aberra-
tions or variants of uncertain significance. We also included 
in our study one patient with significant karyotype findings 
from an examination performed in 2006. Each patient with 
chromosomal aberration underwent comprehensive clinical, 
psychological and radiological evaluations. The Polish version 
of MDS-UPDRS was performed in parkinsonian patients [12]. 
aCGH was performed using a 60  K oligonucleotide 
microarray (CytoSure, ISCA v3 Oxford Gene Technology, 
Oxford, UK). The patient’s DNA was hybridised against the 
control DNA. Labelling and hybridisation were performed 
following the manufacturer’s protocols. 500 ng of DNA was 
labelled and purified on the column’s centrifugal filters. After 
probe denaturation and prehybridisation with Cot-1 DNA, 
hybridisation was performed at 65°C with rotation for 20 hrs. 
After washing, the array was analysed with Agilent scanner 
and Feature Extraction software (Agilent Technologies, Santa 
Clara, CA, USA) and text file outputs from the quantisation 
analysis were imported to CytoSure Interpret software (Oxford 
Gene Technology) for copy number analysis.
This study was approved by the Ethics Committee of the 
Medical University of Warsaw (KB/56/2018) and has been 
performed in accordance with the ethical standards laid down 
in the 1964 Declaration of Helsinki and its later amendments. 
All participants signed an informed consent form for genetic 
examination prior to their inclusion in the study.
Results
Patients with CNV and karyotype aberrations were ana-
lysed in detail. Family history of dystonia or parkinsonism was 
negative in all cases. All the dystonia patients had been born 
from uneventful pregnancies and 5/6 received 10-point Apgar 
scores. In all patients, the onset of dystonia was in childhood. 
The pattern of the progression of dystonia was highly variable 
but in most (5/6) cases it led to generalised dystonia. The key 
clinical features we identified in our cohort, apart from dysto-
nia, were dysmorphic features of the face, which were present 
in five out of six patients (Patients 1–5), hearing impairment 
in two (Patients 4 and 6), and epilepsy in one (Patient 2). The 
pattern of dystonia involvement varied greatly among patients, 
from focal foot dystonia to severe generalised dystonia affect-
ing speech and walking. Patients from the PD group had later 
manifestation of movement disorder than did those in the 
dystonia group, developing their first parkinsonian symptoms 
when aged 37 (Patient 7) and 62 (Patient 8). Both had good 
responses to levodopa treatment without motor fluctuations 
and dyskinesia. The clinical characteristics of all patients are 
set out in Table 1.
Detailed psychological assessment revealed intellectual 
disability in most of the patients, regardless of the type of 
movement disorder. Intellectual disability varied from mild 
to severe. 
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All patients underwent magnetic resonance imaging 
(MRI) studies. Some patients underwent other genetic testing 
prior to aCGH. In three cases, family members also underwent 
aCGH. In other cases, the parents were lost to follow-up. 
Outcomes of these examinations are summarised in Table 1.
Genetic imbalance previously associated with dystonia 
was found in two patients (Patients 1 and 2). Patient 7 was 
diagnosed with deletion involving GPD2 and NR4A2 genes, 
previously discussed in the pathology of PD.
Genetic findings in Patients 3, 4, 5, 6 and 8 were vari-
ants of uncertain clinical significance. In Patient 3, aCGH 
examination revealed duplication involving exons 2–28 of 
the CHL1 gene. In Patient 4, duplication in the long arm of 
chromosome 21 did not include any protein-coding genes. 
Patient 5 was diagnosed with a deletion involving part of 
the NAALADL2 gene. He was affected by severe dystonia 
and intellectual disability. Duplication of exons 3–17 of the 
INTS6L gene was identified in Patient 6, who was suffering 
from dystonia, hearing impairment and intellectual disability. 
Patient 8 had the most severe aberrations. All the findings 
in karyotype and aCGH examinations are summarised in 
Table 1.
The remaining patients with dystonia or parkinsonism 
who underwent aCGH in our Department had normal results.
Discussion
Our study indicates that patients with movement disorders 
and genetic imbalance are a very heterogeneous group in terms 
of clinical manifestation. 
We present eight patients with complex neurological 
symptoms, including early-onset dystonia or parkinsonism. 
Vast differential diagnosis was performed in each case. An-
other important feature present in the majority of patients 
was intellectual disability of varying degree. In some cases, 
chromosomal aberrations included genes previously associated 
with dystonia or parkinsonism which may have effects similar 
to monogenic disorders. The co-occurrence of the symptoms 
of movement disorders, intellectual disability and dysmorphic 
features, after exclusion of common genetic causes, led to 
testing for chromosomal abnormalities. 
Two patients in our cohort (Patients 1 and 2) were di-
agnosed with De Grouchy syndrome (deletion in the 18p or 
18q region). 18p deletion (historically known as De Grouchy 
syndrome type 1) is a recognised cause of dystonia as well as 
other movement disorders, including tics, myoclonus and 
ataxia. The incidence is estimated to be about 1:50,000 live-
born infants [13]. The syndrome is characterised by short 
stature, developmental delay and dysmorphic features — all 
of which were present in our patients. It is considered that 
epilepsy appears more often in cases of the 18q syndrome than 
the 18p syndrome, which is consistent with our observations. 
Dystonia is much less frequent in the 18q syndrome, with only 
anecdotal reports [14].
An absence of the GNAL gene may contribute to dystonia 
in patients with the 18p deletion syndrome. However, the 
frequency of dystonia in 18p deletion patients involving GNAL 
has been estimated at only 3% [15].
The other patients in our group (Patients 3 and 4) were 
diagnosed with chromosomal aberrations in which no linkage 
to dystonia or parkinsonism has been made so far. The sig-
nificance of these findings is therefore uncertain but, in the 
absence of other causes, possible. This is also supported by 
the presence of the additional features of hearing impairment, 
dysmorphic facial features and intellectual disability, strongly 
suggesting the clinical importance of the detected aberrations.
Patient 3 was diagnosed with a microduplication of the 
CHL1 gene. This aberration has already been reported in the 
literature in patients with neurodevelopmental delay, learn-
ing and language difficulties, and seizures. Mild dysmorphic 
features and autism spectrum disorder were also described. 
To the best of our knowledge, neither dystonia nor other 
movement disorders have been described among patients 
with CHL1 duplication. Interestingly, Patient 3’s father was 
an asymptomatic carrier of the mutation. 
In one patient (Patient 4) pronounced myoclonus, hearing 
deficits, dysmorphic facial features, intellectual disability and 
psychiatric symptoms were also observed. Duplication in the 
long arm of chromosome 21 did not encompass regions with 
known genes, therefore this CNV is most likely benign. We 
can however speculate, as several long non-coding RNA are 
encoded in that region, that these could play a role in disease 
mechanisms [16].
Patient 5 was diagnosed with partial deletion in the long 
arm of chromosome 3, which included the NAALADL2 gene. 
A breakpoint of de novo balanced translocation has been 
mapped to that gene in a Cornelia de Lange (CdL) syndrome 
patient. However, further sequencing and screening of the gene 
did not reveal any pathogenic variants in a cohort of patients 
with CdL syndrome [17]. Our patient had dysmorphic cranio-
facial features which were inconsistent with the CdL phenotype 
(steeple skull, high-arched palate), intellectual disability, and 
speech problems. There was no involvement of other organs. 
Patient 6 (a female) had a duplication on chromosome X. 
The duplicated region is not located in a pseudoautosomal 
region, and therefore this raises a question as to whether 
X chromosome inactivation could have an effect on clinical 
expression. In some cases involving larger duplications on the 
X chromosome, a non-random, skewed preferential inac-
tivation of the aberrant X chromosome has been observed. 
However, several cases of smaller duplications have been 
reported where the normal X chromosome was preferentially 
inactivated, leading to severe phenotype [18]. The X chromo-
some inactivation process may lead to a mosaic distribution of 
the active region, harbouring the duplication within the body, 
organs and tissues. The X chromosome inactivation status of 
the specific brain areas should be considered. A brain tissue 
sample was not available for inactivation testing. Madrigal et al. 
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described two patients with partial duplications involving the 
long arm of the X chromosome and intellectual disability, short 
stature, microcephaly and hypopituitarism among others [19].
The deletion identified in Patient 7 contains two pro-
tein-coding genes: NR4A2 and GPD2. GPD2 encoding mito-
chondrial glycerophosphate dehydrogenase has not been un-
ambiguously linked to any movement or neurodevelopmental 
disorder. Deletions encompassing NR4A2 alone, or with GPD2, 
have been found in a few patients with intellectual disability, 
epilepsy, language impairment and/or dysmorphic features. 
Recently, two patients have been reported with loss-of-func-
tion variants in NR4A2 and mild intellectual disability with 
dystonia-parkinsonism in early adulthood [20]. On the mo-
lecular level, the haploinsufficiency caused by deletion in our 
patient should result in a dosage effect similar to the frameshift 
mutations in the two patients described recently [20]. This case 
further strengthens the hypothesis that parkinsonism is a part 
of the clinical picture associated with NR4A2 dysfunction. 
Patient 8 had the most severe aberrations, including many 
genes which could be responsible for parkinsonism. The 
patient had a 104 Mbp duplication on chromosome 1 con-
taining more than 1,000 genes, a 34-gene containing deletion 
encompassing 4.32 Mbp of 10p, and a 3.44 Mbp deletion on 
10q containing 46 genes. The patient’s aberration on chro-
mosome 1 resulted in a duplication of the GBA gene region. 
Heterozygous point mutations are a known parkinsonism risk 
factor, and homozygotes present with the more severe Gau-
cher disease. Some clinical features such as severe depression 
and dementia are consistent with typical GBA-PD patients. 
However, full GBA gene deletions/duplications have not been 
described in PD. Copy number variants in the GBA gene have 
been identified in five parkinsonian patients, although none 
of them had a full gene duplication [21]. 
Conclusions
Chromosomal aberrations may be an under-recognised 
cause of movement disorders. When dystonia or parkinsonism 
is the dominant clinical manifestation, karyotype examination 
may not be considered early. In cases when other features 
dominate, including neurodevelopmental problems, autism 
spectrum disorder, epilepsy or dysmorphic features, aCGH 
examination is prioritised. It is nevertheless important to keep 
in mind that karyotype studies may serve as an important 
first-line diagnostic tool in patients with early-onset movement 
disorders. In selected cases, such patients may require an ex-
amination of the cardiac system, a hearing examination and 
a gastrological assessment to exclude possible comorbidities 
caused by chromosomal aberrations. 
We have identified some rare aberrations that have not 
been previously associated with parkinsonism or dystonia. 
They represent variants of uncertain clinical significance with 
possible association with the disorder. The lack of functional 
studies and whole-exome sequencing in patients is a limitation 
of our study. However, in all cases the general clinical picture 
and neurological symptoms, as well as an absence of the var-
iant in some patient’s parents and gene content, suggest their 
importance. In 4/8 patients, aberrations contained genes in 
which mutations have been previously associated with dystonia 
or parkinsonism. Further studies are needed in the remaining 
cases to investigate whether they play a pathogenic role in the 
disease process.
Chromosomal abnormalities should be mentioned along 
with monogenic autosomal dominant and recessive causes 
of common movement disorders. Chromosomal aberrations 
may produce the same effect on gene expression and result in 
clinical phenotypes of monogenic disorders. It is known that 
small deletions and duplications (1 kbp to 10 Mbp) constitute 
up to 15% of all mutations underlying human monogenic 
diseases [22]. 
In this burgeoning era of precision medicine and vec-
tor-based therapies for the treatment of PD and dystonia, it is 
increasingly important to identify disease backgrounds [23]. 
Therefore, we recommend the introduction of an aCGH 
examination as an important and cost-effective diagnostic tool, 
especially in cases of early-onset dystonia and selected cases 
of parkinsonism with intellectual disability in adult patients.
Funding: This study was funded from statutory funds of the 
Department of Neurology, Faculty of Health Science, Medical 
University of Warsaw. L.M. is supported by the Polish National 
Agency for Academic Exchange Iwanowska’s Fellowship PPN/
IWA/2018/1/00006/U/00001/01.
Conflicts of interest: None.
References
1. Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and 
classification of dystonia: a consensus update. Mov Disord. 2013; 
28(7): 863–873, doi: 10.1002/mds.25475, indexed in Pubmed: 
23649720.
2. Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis 
and treatment of primary dystonias. Eur J Neurol. 2011; 18(1): 5–18, 
doi: 10.1111/j.1468-1331.2010.03042.x, indexed in Pubmed: 
20482602.
3. Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES recommen-
dations for the diagnosis of Parkinson’s disease. European Journal of 
Neurology. 2012; 20(1): 16–34, doi: 10.1111/ene.12022.
4. Yoon WT. Comparison of dystonia between Parkinson’s disease and 
atypical parkinsonism: The clinical usefulness of dystonia distribu-
tion and characteristics in the differential diagnosis of parkinso-
nism. Neurol Neurochir Pol. 2018; 52(1): 48–53, doi: 10.1016/j.
pjnns.2017.11.004, indexed in Pubmed: 29196058.
5. Dale RC, Grattan-Smith P, Nicholson M, et al. Microdeletions detected 
using chromosome microarray in children with suspected genetic mo-
vement disorders: a single-centre study. Dev Med Child Neurol. 2012; 
54(7): 618–623, doi: 10.1111/j.1469-8749.2012.04287.x, inde-
xed in Pubmed: 22515636.
6. Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromo-
somal microarray is a first-tier clinical diagnostic test for individuals 
305www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Monika Figura et al., Movement disorders in chromosomal aberrations
with developmental disabilities or congenital anomalies. Am J Hum 
Genet. 2010; 86(5): 749–764, doi: 10.1016/j.ajhg.2010.04.006, 
indexed in Pubmed: 20466091.
7. Lohmann K, Redin C, Tönnies H, et al. Complex and Dynamic Chro-
mosomal Rearrangements in a Family With Seemingly Non-Mende-
lian Inheritance of Dopa-Responsive Dystonia. JAMA Neurol. 2017; 
74(7): 806–812, doi: 10.1001/jamaneurol.2017.0666, indexed 
in Pubmed: 28558098.
8. Villafuerte B, Natera-de-Benito D, González A, et al. The Brain-
-Lung-Thyroid syndrome (BLTS): A novel deletion in chromosome 
14q13.2-q21.1 expands the phenotype to humoral immunodefi-
ciency. Eur J Med Genet. 2018; 61(7): 393–398, doi: 10.1016/j.
ejmg.2018.02.007, indexed in Pubmed: 29477862.
9. Garraux G, Caberg JH, Vanbellinghen JF, et al. Partial trisomy 4q asso-
ciated with young-onset dopa-responsive parkinsonism. Arch Neurol. 
2012; 69(3): 398–400, doi: 10.1001/archneurol.2011.802, inde-
xed in Pubmed: 22410449.
10. Mok KY, Sheerin U, Simón-Sánchez J, et al. International Parkinson’s 
Disease Genomics Consortium (IPDGC). Deletions at 22q11.2 in 
idiopathic Parkinson’s disease: a combined analysis of genome-
-wide association data. Lancet Neurol. 2016; 15(6): 585–596, 
doi: 10.1016/S1474-4422(16)00071-5, indexed in Pubmed: 
27017469.
11. Robak LA, Du R, Yuan Bo, et al. Integrated sequencing and array compa-
rative genomic hybridization in familial Parkinson disease. Neurol Ge-
net. 2020; 6(5): e498, doi: 10.1212/NXG.0000000000000498, 
indexed in Pubmed: 32802956.
12. Siuda J, Boczarska-Jedynak M, Budrewicz S, et al. Validation of the 
Polish version of the Movement Disorder Society-Unified Parkinson’s 
Disease Rating Scale (MDS-UPDRS). Neurol Neurochir Pol. 2020; 
54(5): 416–425, doi: 10.5603/PJNNS.a2020.0049, indexed in 
Pubmed: 32639019.
13. de Gr, Turleau C. Clinical Atlas of Human Chromosomes. Wiley Medi-
cal: New York. ; 1984.
14. Tezzon F, Zanoni T, Passarin MG, et al. Dystonia in a patient with de-
letion of 18p. Ital J Neurol Sci. 1998; 19(2): 90–93, doi: 10.1007/
BF02427563, indexed in Pubmed: 10935843.
15. Esposito F, Addor MC, Humm AM, et al. GNAL deletion as a probable 
cause of dystonia in a patient with the 18p- syndrome. Parkinso-
nism Relat Disord. 2014; 20(3): 351–352, doi: 10.1016/j.parkrel-
dis.2013.12.005, indexed in Pubmed: 24405754.
16. Riva P, Ratti A, Venturin M. The Long Non-Coding RNAs in Neurodege-
nerative Diseases: Novel Mechanisms of Pathogenesis. Curr Alzhei-
mer Res. 2016; 13(11): 1219–1231, doi: 10.2174/15672050136
66160622112234, indexed in Pubmed: 27338628.
17. Tonkin ET, Smith M, Eichhorn P, et al. A giant novel gene undergo-
ing extensive alternative splicing is severed by a Cornelia de Lange-
-associated translocation breakpoint at 3q26.3. Hum Genet. 2004; 
115(2): 139–148, doi: 10.1007/s00439-004-1134-6, indexed in 
Pubmed: 15168106.
18. Evers C, Mitter D, Strobl-Wildemann G, et al. Duplication Xp11.22-p14 
in females: does X-inactivation help in assessing their significan-
ce? Am J Med Genet A. 2015; 167A(3): 553–562, doi: 10.1002/
ajmg.a.36897, indexed in Pubmed: 25691408.
19. Madrigal I, Fernández-Burriel M, Rodriguez-Revenga L, et al. Xq26.2-
-q26.3 microduplication in two brothers with intellectual disabilities: cli-
nical and molecular characterization. J Hum Genet. 2010; 55(12): 822–
826, doi: 10.1038/jhg.2010.119, indexed in Pubmed: 20861843.
20. Wirth T, Mariani LL, Bergant G, et al. Loss-of-Function Mutations 
in NR4A2 Cause Dopa-Responsive Dystonia Parkinsonism. Mov Di-
sord. 2020; 35(5): 880–885, doi: 10.1002/mds.27982, indexed 
in Pubmed: 31922365.
21. Palumbo O, Fischetto R, Palumbo P, et al. De novo microduplication 
of CHL1 in a patient with non-syndromic developmental phenotypes. 
Mol Cytogenet. 2015; 8: 66, doi: 10.1186/s13039-015-0170-3, 
indexed in Pubmed: 26279679.
22. Vissers LE, Veltman JA, van Kessel AdG, et al. Identification of disease 
genes by whole genome CGH arrays. Hum Mol Genet. 2005; 14 
Spec No. 2: R215–R223, doi: 10.1093/hmg/ddi268, indexed in 
Pubmed: 16244320.
23. Fiandaca MS, Lonser RR, Elder JB, et al. Advancing gene therapies, 
methods, and technologies for Parkinson’s Disease and other neuro-
logical disorders. Neurol Neurochir Pol. 2020; 54(3): 220–231, doi: 
10.5603/PJNNS.a2020.0046, indexed in Pubmed: 32557526.
